Marinus Pharma (MRNS) Misses Q4 EPS by 12c ; Offers Guidance

Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.74), $0.12 worse than the analyst estimate of ($0.62). Revenue for the quarter came in at $7.19 million versus the consensus estimate of $7.97 million.

GUIDANCE:

Marinus Pharma sees FY2024 revenue of $32-34 million, versus the consensus of $42.73 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Hesai Group (HSAI) Tops Q1 EPS by 8c